Pipeline

CitraGen is currently developing several Over-the-counter (OTC) drug products, which are under various stages of development and commercial launch. Some of our OTC drug products are First-to-Market, which will be marketed as Branded Consumer Health care products. These branded OTC drug products are scheduled for commercial launch starting from 4Q 2018. We have filed two trademarks with USPTO for the branding of our specialty OTC products and First-to-market OTC products.

We are also currently developing the following lead NDA products (under the 505(b)2 regulatory pathway). These NDA products have an addressable market of over US$15 billion, globally.